David A. Siegel Geron Corp Transaction History

Two Sigma Advisers, LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$1.2 - $1.5 $83,954 - $104,943	-69,962 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$1.25 - $1.83 $2.97 Million - $4.35 Million	-2,379,246 Reduced 97.14%	69,962 $99,000
Q1 2021 May 17, 2021	BUY	$1.52 - $2.1 $627,304 - $866,670	412,700 Added 20.27%	2,449,208 $3.87 Million
Q4 2020 Feb 16, 2021	BUY	$1.55 - $2.05 $1.56 Million - $2.07 Million	1,008,500 Added 98.1%	2,036,508 $3.24 Million
Q3 2020 Nov 16, 2020	BUY	$1.59 - $2.19 $392,412 - $540,492	246,800 Added 31.59%	1,028,008 $1.79 Million
Q2 2020 Aug 14, 2020	BUY	$1.05 - $2.18 $118,230 - $245,468	112,600 Added 16.84%	781,208 $1.7 Million
Q1 2020 May 15, 2020	BUY	$0.89 - $1.49 $555,489 - $929,977	624,146 Added 1403.77%	668,608 $796,000
Q4 2019 Feb 14, 2020	BUY	$1.27 - $1.54 $56,466 - $68,471	44,462 New	44,462 $60,000
Q1 2019 May 15, 2019	SELL	$1.01 - $1.83 $14,847 - $26,901	-14,700 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$0.98 - $1.85 $14,406 - $27,195	14,700 New	14,700 $15,000
Q3 2018 Nov 14, 2018	SELL	$1.76 - $6.38 $50,160 - $181,830	-28,500 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$3.29 - $4.82 $93,765 - $137,370	28,500 New	28,500 $98,000

276

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.14B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.